Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HBeAg-Negative Chronic Hepatitis B Patients：HBsAg-Positive,HBsAb-Negative,HBeAg-Negative,HBeAb-Positive during screening period and before NA treatment~2. NUC monotherapy (including adefovir and entecavir) for more than 2.5 years,and reached stopping rule in 《Chinese chronic hepatitis B prevention and treatment guidelines》(2010):the patients who achieved undetectable HBV DNA (\<300 copies/mL) with normal alanine aminotransferase (ALT) and the consolidation therapy reached 1.5 years ,total course of the treatment reached 2.5 years can stop NUC therapy~3. Willing to stop the drug, and signed a written informed consent~Exclusion Criteria:~1. HBsAb positive in screening period~2. Compensated or Decompensated liver cirrhosis:with history of cirrhosis before NUC treatment or Child-Pugh score ≥ 5 or Complications of liver cirrhosis such as ascites, hepatic encephalopathy, esophageal gastric varices bleeding~3. Hypersensitivity to interferon(IFN) or its active substance, and ineligible to IFN~4. A history of immunoregulation drug therapy within one year before entry including IFN and so on.~5. Coinfection with HAV、HCV、HDV、HEV 、HIV or with Other chronic liver diseases such as Alcoholic Liver Disease,Inherited Metabolic Liver Disease,Drug induced Liver Disease and nonalcoholic fatty liver~6. Autoimmune disease including Autoimmune hepatitis and Psoriasis and so on.~7. Hepatocellular carcinoma(HCC) or alpha feto protein(AFP) levels more than 100 ng/ml and Hepatic malignant potential of Imaging examination or AFP levels more than 100 ng/ml for 3 months~8. A neutrophil count of less than 1500 per cubic millimeter or a platelet count of less than 90,000 per cubic millimeter~9. A serum creatinine level that was more than 1.5 times the upper limit of the normal range~10. With other malignant tumors(exclude the cured ones)~11. Severe organ dysfunction~12. With severe psychiatric condition or nervous disease such as epilepsy, depression, mania, epilepsy, schizophrenia and so on~13. Uncontrolled diabetes, hypertension or thyroid disease~14. Pregnant women and lactating women or patients with pregnancy plans and not willing to use contraception during the study period~15. Participate in other clinical studies at the same time~16. Patients unsuitable for the research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Controlled Group (Type: NO_INTERVENTION): Discontinue the NA treatment and follow up for 96 weeks
- Pegasys 48 weeks (Type: EXPERIMENTAL): Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).